TISIDB

Summary
Symbol	HDAC2
Name	histone deacetylase 2
Aliases	YAF1; HD2; YY1-associated factor 1; transcriptional regulator homolog RPD3
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus Cytoplasm
Domain	PF00850 Histone deacetylase domain
Function	Responsible for the deacetylation of lysine residues on the N-terminal part of the core histones (H2A, H2B, H3 and H4). Histone deacetylation gives a tag for epigenetic repression and plays an important role in transcriptional regulation, cell cycle progression and developmental events. Histone deacetylases act via the formation of large multiprotein complexes. Forms transcriptional repressor complexes by associating with MAD, SIN3, YY1 and N-COR. Interacts in the late S-phase of DNA-replication with DNMT1 in the other transcriptional repressor complex composed of DNMT1, DMAP1, PCNA, CAF1. Deacetylates TSHZ3 and regulates its transcriptional repressor activity. Component of a RCOR/GFI/KDM1A/HDAC complex that suppresses, via histone deacetylase (HDAC) recruitment, a number of genes implicated in multilineage blood cell development. May be involved in the transcriptional repression of circadian target genes, such as PER1, mediated by CRY1 through histone deacetylation. Involved in MTA1-mediated transcriptional corepression of TFF1 and CDKN1A.

> Gene Ontology [ TOP ]
Biological Process	GO:0000302 response to reactive oxygen species GO:0001101 response to acid chemical GO:0001654 eye development GO:0001819 positive regulation of cytokine production GO:0001837 epithelial to mesenchymal transition GO:0001942 hair follicle development GO:0001975 response to amphetamine GO:0002237 response to molecule of bacterial origin GO:0003012 muscle system process GO:0003300 cardiac muscle hypertrophy GO:0006338 chromatin remodeling GO:0006342 chromatin silencing GO:0006344 maintenance of chromatin silencing GO:0006473 protein acetylation GO:0006476 protein deacetylation GO:0006979 response to oxidative stress GO:0007259 JAK-STAT cascade GO:0007260 tyrosine phosphorylation of STAT protein GO:0007423 sensory organ development GO:0007596 blood coagulation GO:0007599 hemostasis GO:0007623 circadian rhythm GO:0008544 epidermis development GO:0009266 response to temperature stimulus GO:0009408 response to heat GO:0009913 epidermal cell differentiation GO:0010001 glial cell differentiation GO:0010035 response to inorganic substance GO:0010712 regulation of collagen metabolic process GO:0010714 positive regulation of collagen metabolic process GO:0010717 regulation of epithelial to mesenchymal transition GO:0010718 positive regulation of epithelial to mesenchymal transition GO:0010720 positive regulation of cell development GO:0010721 negative regulation of cell development GO:0010869 regulation of receptor biosynthetic process GO:0010870 positive regulation of receptor biosynthetic process GO:0010975 regulation of neuron projection development GO:0010977 negative regulation of neuron projection development GO:0014013 regulation of gliogenesis GO:0014015 positive regulation of gliogenesis GO:0014074 response to purine-containing compound GO:0014075 response to amine GO:0014896 muscle hypertrophy GO:0014897 striated muscle hypertrophy GO:0016358 dendrite development GO:0016458 gene silencing GO:0016570 histone modification GO:0016575 histone deacetylation GO:0018108 peptidyl-tyrosine phosphorylation GO:0018205 peptidyl-lysine modification GO:0018212 peptidyl-tyrosine modification GO:0018394 peptidyl-lysine acetylation GO:0022404 molting cycle process GO:0022405 hair cycle process GO:0030326 embryonic limb morphogenesis GO:0030534 adult behavior GO:0031000 response to caffeine GO:0031345 negative regulation of cell projection organization GO:0032496 response to lipopolysaccharide GO:0032526 response to retinoic acid GO:0032612 interleukin-1 production GO:0032640 tumor necrosis factor production GO:0032652 regulation of interleukin-1 production GO:0032680 regulation of tumor necrosis factor production GO:0032732 positive regulation of interleukin-1 production GO:0032760 positive regulation of tumor necrosis factor production GO:0032800 receptor biosynthetic process GO:0032922 circadian regulation of gene expression GO:0032963 collagen metabolic process GO:0032964 collagen biosynthetic process GO:0032965 regulation of collagen biosynthetic process GO:0032967 positive regulation of collagen biosynthetic process GO:0034599 cellular response to oxidative stress GO:0034605 cellular response to heat GO:0034614 cellular response to reactive oxygen species GO:0035094 response to nicotine GO:0035107 appendage morphogenesis GO:0035108 limb morphogenesis GO:0035113 embryonic appendage morphogenesis GO:0035601 protein deacylation GO:0036296 response to increased oxygen levels GO:0040029 regulation of gene expression, epigenetic GO:0042063 gliogenesis GO:0042220 response to cocaine GO:0042303 molting cycle GO:0042475 odontogenesis of dentin-containing tooth GO:0042476 odontogenesis GO:0042493 response to drug GO:0042503 tyrosine phosphorylation of Stat3 protein GO:0042509 regulation of tyrosine phosphorylation of STAT protein GO:0042516 regulation of tyrosine phosphorylation of Stat3 protein GO:0042517 positive regulation of tyrosine phosphorylation of Stat3 protein GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein GO:0042542 response to hydrogen peroxide GO:0042633 hair cycle GO:0042733 embryonic digit morphogenesis GO:0043010 camera-type eye development GO:0043044 ATP-dependent chromatin remodeling GO:0043112 receptor metabolic process GO:0043279 response to alkaloid GO:0043392 negative regulation of DNA binding GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity GO:0043543 protein acylation GO:0043586 tongue development GO:0043587 tongue morphogenesis GO:0043588 skin development GO:0044236 multicellular organism metabolic process GO:0044246 regulation of multicellular organismal metabolic process GO:0044253 positive regulation of multicellular organismal metabolic process GO:0044259 multicellular organismal macromolecule metabolic process GO:0044708 single-organism behavior GO:0045342 MHC class II biosynthetic process GO:0045346 regulation of MHC class II biosynthetic process GO:0045347 negative regulation of MHC class II biosynthetic process GO:0045471 response to ethanol GO:0045665 negative regulation of neuron differentiation GO:0045685 regulation of glial cell differentiation GO:0045687 positive regulation of glial cell differentiation GO:0045814 negative regulation of gene expression, epigenetic GO:0045862 positive regulation of proteolysis GO:0046425 regulation of JAK-STAT cascade GO:0046427 positive regulation of JAK-STAT cascade GO:0048149 behavioral response to ethanol GO:0048511 rhythmic process GO:0048709 oligodendrocyte differentiation GO:0048713 regulation of oligodendrocyte differentiation GO:0048714 positive regulation of oligodendrocyte differentiation GO:0048736 appendage development GO:0048762 mesenchymal cell differentiation GO:0050730 regulation of peptidyl-tyrosine phosphorylation GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation GO:0050768 negative regulation of neurogenesis GO:0050769 positive regulation of neurogenesis GO:0050773 regulation of dendrite development GO:0050817 coagulation GO:0050878 regulation of body fluid levels GO:0051090 regulation of sequence-specific DNA binding transcription factor activity GO:0051098 regulation of binding GO:0051100 negative regulation of binding GO:0051101 regulation of DNA binding GO:0051961 negative regulation of nervous system development GO:0051962 positive regulation of nervous system development GO:0055093 response to hyperoxia GO:0060173 limb development GO:0060485 mesenchyme development GO:0060788 ectodermal placode formation GO:0060789 hair follicle placode formation GO:0060996 dendritic spine development GO:0060998 regulation of dendritic spine development GO:0061000 negative regulation of dendritic spine development GO:0061029 eyelid development in camera-type eye GO:0061196 fungiform papilla development GO:0061197 fungiform papilla morphogenesis GO:0061198 fungiform papilla formation GO:0070301 cellular response to hydrogen peroxide GO:0070482 response to oxygen levels GO:0070932 histone H3 deacetylation GO:0070933 histone H4 deacetylation GO:0071229 cellular response to acid chemical GO:0071300 cellular response to retinoic acid GO:0071396 cellular response to lipid GO:0071407 cellular response to organic cyclic compound GO:0071417 cellular response to organonitrogen compound GO:0071559 response to transforming growth factor beta GO:0071560 cellular response to transforming growth factor beta stimulus GO:0071696 ectodermal placode development GO:0071697 ectodermal placode morphogenesis GO:0071706 tumor necrosis factor superfamily cytokine production GO:0071867 response to monoamine GO:0071868 cellular response to monoamine stimulus GO:0071869 response to catecholamine GO:0071870 cellular response to catecholamine stimulus GO:0072331 signal transduction by p53 class mediator GO:0090596 sensory organ morphogenesis GO:0097305 response to alcohol GO:0097696 STAT cascade GO:0098732 macromolecule deacylation GO:0098773 skin epidermis development GO:1901796 regulation of signal transduction by p53 class mediator GO:1901983 regulation of protein acetylation GO:1901984 negative regulation of protein acetylation GO:1903350 response to dopamine GO:1903351 cellular response to dopamine GO:1903555 regulation of tumor necrosis factor superfamily cytokine production GO:1903557 positive regulation of tumor necrosis factor superfamily cytokine production GO:1904892 regulation of STAT cascade GO:1904894 positive regulation of STAT cascade GO:2000171 negative regulation of dendrite development GO:2000756 regulation of peptidyl-lysine acetylation GO:2000757 negative regulation of peptidyl-lysine acetylation
Molecular Function	GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding GO:0000980 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0000987 core promoter proximal region sequence-specific DNA binding GO:0001047 core promoter binding GO:0001085 RNA polymerase II transcription factor binding GO:0001103 RNA polymerase II repressing transcription factor binding GO:0001158 enhancer sequence-specific DNA binding GO:0001159 core promoter proximal region DNA binding GO:0003682 chromatin binding GO:0004407 histone deacetylase activity GO:0008134 transcription factor binding GO:0016810 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds GO:0016811 hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in linear amides GO:0017136 NAD-dependent histone deacetylase activity GO:0019213 deacetylase activity GO:0031072 heat shock protein binding GO:0031078 histone deacetylase activity (H3-K14 specific) GO:0031490 chromatin DNA binding GO:0031491 nucleosome binding GO:0031492 nucleosomal DNA binding GO:0032041 NAD-dependent histone deacetylase activity (H3-K14 specific) GO:0033558 protein deacetylase activity GO:0034979 NAD-dependent protein deacetylase activity GO:0035326 enhancer binding GO:0043566 structure-specific DNA binding GO:0051059 NF-kappaB binding GO:0070491 repressing transcription factor binding
Cellular Component	GO:0000118 histone deacetylase complex GO:0000785 chromatin GO:0000790 nuclear chromatin GO:0016580 Sin3 complex GO:0016581 NuRD complex GO:0017053 transcriptional repressor complex GO:0031519 PcG protein complex GO:0034708 methyltransferase complex GO:0035097 histone methyltransferase complex GO:0035098 ESC/E(Z) complex GO:0044454 nuclear chromosome part GO:0070603 SWI/SNF superfamily-type complex GO:0070822 Sin3-type complex GO:0090545 CHD-type complex GO:0090568 nuclear transcriptional repressor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04110 Cell cycle hsa04330 Notch signaling pathway hsa04919 Thyroid hormone signaling pathway
Reactome	R-HSA-3247509: Chromatin modifying enzymes R-HSA-4839726: Chromatin organization R-HSA-2894862: Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants R-HSA-2644606: Constitutive Signaling by NOTCH1 PEST Domain Mutants R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-427389: ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression R-HSA-212165: Epigenetic regulation of gene expression R-HSA-983231: Factors involved in megakaryocyte development and platelet production R-HSA-74160: Gene Expression R-HSA-212436: Generic Transcription Pathway R-HSA-3214815: HDACs deacetylate histones R-HSA-109582: Hemostasis R-HSA-2122947: NOTCH1 Intracellular Domain Regulates Transcription R-HSA-5250941: Negative epigenetic regulation of rRNA expression R-HSA-427413: NoRC negatively regulates rRNA expression R-HSA-5250913: Positive epigenetic regulation of rRNA expression R-HSA-73854: RNA Polymerase I Promoter Clearance R-HSA-73864: RNA Polymerase I Transcription R-HSA-73762: RNA Polymerase I Transcription Initiation R-HSA-504046: RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription R-HSA-5633007: Regulation of TP53 Activity R-HSA-6804758: Regulation of TP53 Activity through Acetylation R-HSA-162582: Signal Transduction R-HSA-157118: Signaling by NOTCH R-HSA-1980143: Signaling by NOTCH1 R-HSA-2894858: Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer R-HSA-2644602: Signaling by NOTCH1 PEST Domain Mutants in Cancer R-HSA-2644603: Signaling by NOTCH1 in Cancer R-HSA-166520: Signalling by NGF R-HSA-3700989: Transcriptional Regulation by TP53 R-HSA-193704: p75 NTR receptor-mediated signalling R-HSA-193670: p75NTR negatively regulates cell cycle via SC1

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04110 Cell cycle
hsa04330 Notch signaling pathway
hsa04919 Thyroid hormone signaling pathway

Reactome

R-HSA-3247509: Chromatin modifying enzymes
R-HSA-4839726: Chromatin organization
R-HSA-2894862: Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
R-HSA-2644606: Constitutive Signaling by NOTCH1 PEST Domain Mutants
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-427389: ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression
R-HSA-212165: Epigenetic regulation of gene expression
R-HSA-983231: Factors involved in megakaryocyte development and platelet production
R-HSA-74160: Gene Expression
R-HSA-212436: Generic Transcription Pathway
R-HSA-3214815: HDACs deacetylate histones
R-HSA-109582: Hemostasis
R-HSA-2122947: NOTCH1 Intracellular Domain Regulates Transcription
R-HSA-5250941: Negative epigenetic regulation of rRNA expression
R-HSA-427413: NoRC negatively regulates rRNA expression
R-HSA-5250913: Positive epigenetic regulation of rRNA expression
R-HSA-73854: RNA Polymerase I Promoter Clearance
R-HSA-73864: RNA Polymerase I Transcription
R-HSA-73762: RNA Polymerase I Transcription Initiation
R-HSA-504046: RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription
R-HSA-5633007: Regulation of TP53 Activity
R-HSA-6804758: Regulation of TP53 Activity through Acetylation
R-HSA-162582: Signal Transduction
R-HSA-157118: Signaling by NOTCH
R-HSA-1980143: Signaling by NOTCH1
R-HSA-2894858: Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
R-HSA-2644602: Signaling by NOTCH1 PEST Domain Mutants in Cancer
R-HSA-2644603: Signaling by NOTCH1 in Cancer
R-HSA-166520: Signalling by NGF
R-HSA-3700989: Transcriptional Regulation by TP53
R-HSA-193704: p75 NTR receptor-mediated signalling
R-HSA-193670: p75NTR negatively regulates cell cycle via SC1

Summary
Symbol	HDAC2
Name	histone deacetylase 2
Aliases	YAF1; HD2; YY1-associated factor 1; transcriptional regulator homolog RPD3
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between HDAC2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between HDAC2 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
19010907	Colorectal Carcinoma	Inhibit immunity	Enzymatic degradation of PGE(2) involves the NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH). We report here that treatment of CRC cells with histone deacetylase (HDAC) inhibitors, including sodium butyrate and valproic acid, induces 15-PGDH expression. Additionally, we show that pretreatment of CRC cells with HDAC inhibitors can block epidermal growth factor-mediated or Snail-mediated transcriptional repression of 15-PGDH.

Summary
Symbol	HDAC2
Name	histone deacetylase 2
Aliases	YAF1; HD2; YY1-associated factor 1; transcriptional regulator homolog RPD3
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of HDAC2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	HDAC2
Name	histone deacetylase 2
Aliases	YAF1; HD2; YY1-associated factor 1; transcriptional regulator homolog RPD3
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of HDAC2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.088	0.675
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.022	0.99
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.169	0.902
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.131	0.688
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.401	0.838
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.206	0.936
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.021	0.963
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.24	0.897
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.24	0.906
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.118	0.942
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.817	0.733
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.136	0.0891

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of HDAC2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	11.1	0.0181
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	11.1	0.0286
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	1

Summary
Symbol	HDAC2
Name	histone deacetylase 2
Aliases	YAF1; HD2; YY1-associated factor 1; transcriptional regulator homolog RPD3
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HDAC2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	HDAC2
Name	histone deacetylase 2
Aliases	YAF1; HD2; YY1-associated factor 1; transcriptional regulator homolog RPD3
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HDAC2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HDAC2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	HDAC2
Name	histone deacetylase 2
Aliases	YAF1; HD2; YY1-associated factor 1; transcriptional regulator homolog RPD3
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HDAC2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	HDAC2
Name	histone deacetylase 2
Aliases	YAF1; HD2; YY1-associated factor 1; transcriptional regulator homolog RPD3
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of HDAC2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	HDAC2
Name	histone deacetylase 2
Aliases	YAF1; HD2; YY1-associated factor 1; transcriptional regulator homolog RPD3
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between HDAC2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	HDAC2
Name	histone deacetylase 2
Aliases	YAF1; HD2; YY1-associated factor 1; transcriptional regulator homolog RPD3
Chromosomal Location	6q21
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting HDAC2 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting HDAC2.

ID	Name	Drug Type	Targets	#Targets
DB00227	Lovastatin	Small Molecule	HDAC2, HMGCR, ITGAL	3
DB00277	Theophylline	Small Molecule	ADORA1, ADORA2A, ADORA2B, CPNE1, HDAC2, HM13, NOMO1, PARP1, PDE3A, ......	14
DB00313	Valproic Acid	Small Molecule	ABAT, ACADSB, ALDH5A1, HDAC2, HDAC9, OGDH, PPARA, PPARD, PPARG, SC ......	23
DB01223	Aminophylline	Small Molecule	ADORA1, ADORA3, HDAC2, PDE3A	4
DB01303	Oxtriphylline	Small Molecule	ADORA1, ADORA2A, HDAC2, PDE3A, PDE4A	5
DB02546	Vorinostat	Small Molecule	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8	5
DB05015	Belinostat	Small Molecule	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, H ......	11
DB05223	Pracinostat	Small Molecule	HDAC1, HDAC2, HDAC3, HDAC6	4
DB06176	Romidepsin	Small Molecule	ABCC1, HDAC1, HDAC2, HDAC4, HDAC6	5
DB06603	Panobinostat	Small Molecule	HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, H ......	11
DB09091	Tixocortol	Small Molecule	HDAC2, NR3C1	2
DB11830	Mocetinostat	Small Molecule	HDAC1, HDAC2, HDAC3	3

Browse HDAC2